Beyond DTx: Is Pharma Missing the Bigger Picture in Digital Health?
Disrupting pharma's digital innovation mindset Digital Therapeutics (DTx) have stormed onto the healthcare scene, promising groundbreaking change with their clinically validated, tech-driven interventions. But here’s the burning question: Is this the only path to digital health innovation for pharma? Are companies locking themselves into an expensive, heavily regulated, slow-moving gamble, while more flexible and scalable solutions with potentially greater impact on patient outcomes are waiting in the wings?
The Digital Therapeutics Alliance (DTA) defines DTx as “software intended to treat or alleviate a disease, disorder, condition, or injury through a medical intervention that has a demonstrable positive therapeutic impact” [1].
Yet, despite the buzz, we must ask—are DTx the exclusive gateway to the future, or could pharma leap ahead by exploring broader, more adaptable digital tools that deliver impactful results faster?
Download our latest position paper to find out!
See also
Observia co-construit une formation sur les programmes patient avec l'IFIS
From Real-World Data to Real-World Evidence: why and how
Scalability, the one way to multiply an e-health solution's impact
Need more information?
A burning question, a specific request, a great project to share with us? Get in touch, our teams are here to help!
